Market Overview

Global Biosimilars Market (2020 to 2025) - New Indications and the Patent Expiry of Biologic Products Present Lucrative Opportunities

Share:

DUBLIN, April 1, 2020 /PRNewswire/ -- The "Biosimilars Market by Product (Insulin, Interferon, Etanercept, Infliximab, Rituximab, Glucagon, Calcitonin), Manufacturing (In-house, Contract) & Indication (Oncology, Chronic Disease, Blood Disorder, Autoimmune Disease), Region - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global biosimilars market size is projected to reach USD 35.7 billion by 2025 from USD 11.8 billion in 2020, at a CAGR of 24.7%.

The biosimilars market by service is categorized into insulin, monoclonal antibodies, recombinant human growth hormone (rhGH), granulocyte colony-stimulating factor, interferon, erythropoietin, etanercept, follitropin, glucagon, calcitonin, and teriparatide and enoxaparin sodium. The monoclonal antibodies segment is expected to register the highest CAGR during the forecast period. The growth of this segment is driven mainly by the increasing number of product launches/approvals, rising incidences of cancer diseases.

The contract manufacturing segment is estimated to grow at a rapid rate during the analysis period.

Based on the treatment site, the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The contract manufacturing segment is expected to remain the fastest-growing segment of the global market during the biosimilars period. Its benefits, particularly for small players in the market or those that do not have sufficient infrastructure and resources for efficient manufacturing, are driving growth.

Asia Pacific is estimated to register the highest CAGR during the study period.

Geographically, the biosimilars market is dominated by Europe and followed by Asia Pacific in 2019. However, the Asia Pacific region is estimated to grow at the fastest rate during forecast to period. The rising aging population, coupled with the massive demand for cost-effective alternative pharmaceuticals, will drive the market in the region over the forecast period.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Biosimilars Market Overview
4.2 North America: Biosimilars Market, by Product, 2019
4.3 Geographical Snapshot of the Biosimilars Market

5 Regulatory Outlook
5.1 North America
5.1.1 US
5.1.2 Canada
5.2 Europe
5.3 Asia Pacific
5.3.1 China
5.3.2 India
5.3.3 Japan
5.3.4 South Korea
5.3.5 Australia
5.4 Rest of the World
5.4.1 Brazil
5.4.2 Mexico
5.4.3 Argentina
5.4.4 Saudi Arabia

6 Market Overview
6.1 Introduction
6.2 Market Dynamics
6.2.1 Drivers
6.2.1.1 Increasing Demand for Biosimilar Drugs
6.2.1.2 Rising Incidence of Chronic Diseases
6.2.2 Restraints
6.2.2.1 Complexities in Manufacturing
6.2.2.2 Resistance From Biologic Manufacturers
6.2.3 Opportunities
6.2.3.1 Emerging Markets
6.2.3.2 New Indications and the Patent Expiry of Biologic Products
6.2.4 Challenges
6.2.4.1 Stringent Regulatory Requirements
6.2.5 Trends
6.2.5.1 Collaborations for Biosimilar Research and Clinical Trials

7 Biosimilars Market, by Product
7.1 Introduction
7.2 Monoclonal Antibodies
7.2.1 Infliximab
7.2.1.1 Infliximab Accounted for the Largest Share of the Monoclonal Antibodies Market
7.2.2 Rituximab
7.2.2.1 Rising Incidence of Autoimmune Diseases and Cancer Are Key Drivers for the Market Growth
7.2.3 Trastuzumab
7.2.3.1 Rising Incidences of Cancer will Drive Market Growth
7.2.4 Adalimumab
7.2.4.1 Adalimumab will Register the Highest Cagr in the Monoclonal Antibodies Market
7.2.5 Other Monoclonal Antibodies
7.3 Insulin
7.3.1 Increasing Incidence of Diabetes will Support Market Growth
7.4 Granulocyte Colony-Stimulating Factor
7.5 Erythropoietin
7.5.1 Rising Incidence of Blood Disorders will Drive Market Growth
7.6 Recombinant Human Growth Hormone
7.6.1 Market Growth is Driven Primarily by the Increasing Incidence of Growth Deficiency Disorders
7.7 Etanercept
7.7.1 Apac Market for Etanercept will Show the Highest Growth in the Forecast Period
7.8 Follitropin
7.8.1 Increasing Application of Follitropin in Infertility Treatment will Drive Market Growth
7.9 Teriparatide
7.9.1 Increasing Incidence of Osteoporosis is the Main Growth Driver for This Market
7.10 Interferons
7.10.1 Market Growth is Supported by the Rising Incidence of Infectious Diseases
7.11 Enoxaparin Sodium
7.11.1 Wide Range of Applications Have Supported the Demand for Enoxaparin Sodium Biosimilars
7.12 Glucagon
7.12.1 Sandoz is a Major Player in the Glucagon Biosimilars Market
7.13 Calcitonin
7.13.1 Increasing Incidence of Osteoporosis will Drive the Market

8 Biosimilars Market, by Type of Manufacturing
8.1 Introduction
8.2 In-House Manufacturing
8.2.1 Cost-Effectiveness Makes In-House Manufacturing Highly Preferable for Most Market Players
8.3 Contract Manufacturing
8.3.1 Outsourcing Production Enables Companies to Focus on Core Competency and Provides Cost-Benefits

9 Biosimilars Market, by Indication
9.1 Introduction
9.2 Oncology
9.2.1 Rising Burden of Cancer and Growing Incidence Have Driven Demand for Biosimilars
9.3 Chronic Diseases
9.3.1 High Efficacy of Biosimilars Has Driven Research Into Applications in Chronic Disease Treatment
9.4 Autoimmune Diseases
9.4.1 Growing Research Activity for Autoimmune Disease Indications will Favor Market Growth
9.5 Blood Disorders
9.5.1 Possibility of Cost-Reductions in Blood Disorder Treatment will Support Market Demand for Biosimilars
9.6 Growth Hormone Deficiency
9.6.1 Growing Cases of Gh Deficiency Drives Demand for Biosimilars
9.7 Infectious Diseases
9.7.1 Asia Pacific Shows Highest Demand for Biosimilars in This Segment
9.8 Other Indications

10 Biosimilars Market, by Region
10.1 Introduction
10.2 Europe
10.2.1 UK
10.2.1.1 the UK Holds the Largest Share of the Biosimilars Market in Europe
10.2.2 France
10.2.2.1 Rising Geriatric Population will Drive Market Growth
10.2.3 Germany
10.2.3.1 the Presence of a Favorable Pricing System Has Supported Biosimilar Adoption in Germany
10.2.4 Italy
10.2.4.1 Rising Geriatric Population in Italy will Support Market Growth
10.2.5 Spain
10.2.5.1 R&D Investments for the Development of Innovative Drugs is a Key Growth Driver in the Spanish Market
10.2.6 Rest of Europe
10.3 Asia Pacific
10.3.1 India
10.3.1.1 India Holds the Largest Share of the Apac Market
10.3.2 China
10.3.2.1 China Accounts for the Second-Largest Share of the Apac Market
10.3.3 South Korea
10.3.3.1 Rising Incidences of Chronic Diseases Are Expected to Drive the Market in South Korea
10.3.4 Japan
10.3.4.1 Growing Geriatric Population is Expected to Drive the Market in Japan
10.3.5 Australia
10.3.5.1 Increasing Number of Product Launches by Companies will Drive Market Growth
10.3.6 Rest of Asia Pacific
10.4 North America
10.4.1 US
10.4.1.1 US will Dominate the North American Biosimilars Market
10.4.2 Canada
10.4.2.1 Increasing Incidences of Chronic Diseases will Drive Market Growth in Canada
10.5 Latin America
10.5.1 Rising Incidences of Cancer will Drive Market Growth
10.6 Middle East and Africa
10.6.1 Favorable Healthcare Reforms and Infrastructural Development will Favor Market Growth

11 Competitive Landscape
11.1 Overview
11.2 Market Share Analysis, 2018
11.3 Competitive Scenario
11.3.1 Product Launches/Product Approvals
11.3.2 Partnerships, Collaborations, and Agreements
11.3.3 Acquisitions
11.3.4 Expansions
11.4 Competitive Leadership Mapping (2018)
11.4.1 Vendor Inclusion Criteria
11.4.2 Visionary Leaders
11.4.3 Innovators
11.4.4 Dynamic Differentiators
11.4.5 Emerging Companies

12 Company Profiles
12.1 Sandoz
12.2 Pfizer
12.3 Eli Lilly
12.4 Teva Pharmaceutical
12.5 Celltrion
12.6 Biocon
12.7 Amgen
12.8 Samsung Biologics
12.9 Mylan
12.10 Dr. Reddy's Laboratories
12.11 Stada Arzneimittel Ag
12.12 Coherus Biosciences
12.13 Biocad
12.14 Amega Biotech
12.15 Probiomed
12.16 Boehringer Ingelheim
12.17 Apotex
12.18 Fresenius Kabi
12.19 Gedeon Richter
12.20 Mabxience

For more information about this report visit https://www.researchandmarkets.com/r/rjgneq

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-biosimilars-market-2020-to-2025---new-indications-and-the-patent-expiry-of-biologic-products-present-lucrative-opportunities-301033515.html

SOURCE Research and Markets

View Comments and Join the Discussion!
 
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com